Report Content
Chapter 1. Methodology
1.1. Methodology
1.1.1. Methodology
1.1.2. Market definition
1.1.3. Forecast parameters
1.1.4. Data sources
1.1.4.1. Primary
1.1.4.2. Secondary
Chapter 2. Executive Summary
2.1. North America & Europe PEGylated drugs industry 3600 synopsis, 2013 - 2024 (USD Million)
2.1.1. Business trends
2.1.2. Disease indication trends
2.1.3. Type trends
2.1.4. Regional trends
Chapter 3. North America & Europe PEGylated Drugs Industry Insights
3.1. Industry segmentation
3.2. Industry impact forces
3.2.1. Growth drivers
3.2.1.1. Increasing prevalence of cancer in developed regions
3.2.1.2. Rising R&D spending by biotechnology & pharmaceutical companies in U.S. and Europe
3.2.1.3. Growing biologics sector in the developed economies
3.2.2. Industry pitfalls & challenges
3.2.2.1. Drug recalls in the U.S. & Europe
3.2.2.2. Adverse drug reactions
3.3. Growth potential analysis
3.3.1. By disease indication
3.3.2. By type
3.4. Regulatory landscape
3.4.1. U.S.
3.4.2. Europe
3.5. Porter's analysis
3.6. Pipeline analysis
3.7. Competitive landscape, 2017
3.7.1. Strategy dashboard
3.8. PESTEL analysis
Chapter 4. North America & Europe PEGylated Drugs Market, By Disease Indication
4.1. North America & Europe PEGylated drugs market share by disease indication, 2017 & 2024
4.2. Cancer
4.2.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
4.3. Hepatitis
4.3.1. Market estimates and forecast, by country, 2013 – 2024 (USD Million)
4.4. Multiple sclerosis
4.4.1. Market estimates and forecast, by country, 2013 – 2024 (USD Million)
4.5. Gastrointestinal disorders
4.5.1. Market estimates and forecast, by country, 2013 – 2024 (USD Million)
4.6. Others
4.6.1. Market estimates and forecast, by country, 2013 – 2024 (USD Million)
Chapter 5. North America & Europe PEGylated Drugs, By Type
5.1. North America & Europe PEGylated drugs market share by type, 2017 & 2024
5.2. Monoclonal antibodies (mAbs)
5.2.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
5.3. Colony stimulating factors
5.3.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
5.4. Interferons
5.4.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
5.5. Others
5.5.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
Chapter 6. North America & Europe PEGylated Drugs Market, By Country
6.1. North America & Europe PEGylated drugs market share by country, 2017 & 2024
6.2. North America
6.2.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
6.2.2. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.2.3. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.2.4. U.S.
6.2.4.1. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.2.4.2. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.2.5. Canada
6.2.5.1. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.2.5.2. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.3. Europe
6.3.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
6.3.2. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.3.3. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.3.4. Germany
6.3.4.1. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.3.4.2. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.3.5. France
6.3.5.1. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.3.5.2. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.3.6. UK
6.3.6.1. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.3.6.2. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
6.3.7. Spain
6.3.7.1. Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)
6.3.7.2. Market estimates and forecast, by type, 2013 - 2024 (USD Million)
Chapter 7. Company Profiles
7.1. Merck KGaA
7.1.1. Business overview
7.1.2. Financial data
7.1.3. Product landscape
7.1.4. Strategic outlook
7.1.5. SWOT analysis
7.2. Biogen Inc.
7.2.1. Business overview
7.2.2. Financial data
7.2.3. Product landscape
7.2.4. Strategic outlook
7.2.5. SWOT analysis
7.3. AstraZeneca
7.3.1. Business overview
7.3.2. Financial data
7.3.3. Product landscape
7.3.4. Strategic outlook
7.3.5. SWOT analysis
7.4. UCB
7.4.1. Business overview
7.4.2. Financial data
7.4.3. Product landscape
7.4.4. Strategic outlook
7.4.5. SWOT analysis
7.5. Amgen
7.5.1. Business overview
7.5.2. Financial data
7.5.3. Product landscape
7.5.4. Strategic outlook
7.5.5. SWOT analysis
7.6. Sigma Tau (Leadiant Biosciences)
7.6.1. Business overview
7.6.2. Financial data
7.6.3. Product landscape
7.6.4. Strategic outlook
7.6.5. SWOT analysis
7.7. Roche
7.7.1. Business overview
7.7.2. Financial data
7.7.3. Product landscape
7.7.4. Strategic outlook
7.7.5. SWOT analysis
7.8. Shire Group
7.8.1. Business overview
7.8.2. Financial data
7.8.3. Product landscape
7.8.4. Strategic outlook
7.8.5. SWOT analysis
7.9. Pfizer
7.9.1. Business overview
7.9.2. Financial data
7.9.3. Product landscape
7.9.4. Strategic outlook
7.9.5. SWOT analysis
7.10. Novo Nordisk
7.10.1. Business overview
7.10.2. Financial data
7.10.3. Product landscape
7.10.4. Strategic outlook
7.10.5. SWOT analysis
